Definium Therapeutics Begins Phase 3 DT120-ODT Study
WALTHAM, Mass., May 12, 2026 Definium Therapeutics announced that the first patient has been dosed in the pivotal ASCEND...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
WALTHAM, Mass., May 12, 2026 Definium Therapeutics announced that the first patient has been dosed in the pivotal ASCEND...
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
TITUSVILLE, NEW JERSEY, May 04, 2026 Johnson & Johnson has announced new findings demonstrating that CAPLYTA® (lumateperone) achieved the...
BOSTON, Massachusetts, March 26, 2026 PureTech Health has announced that its founded entity, Seaport Therapeutics, has published first-in-human clinical...
OSAKA, Japan, March 19, 2026 Shionogi & Co., Ltd. has officially announced the commercial launch of ZURZUVAE® (zuranolone) 30...
Chatham, N.J. — Nov. 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
Chatham, New Jersey, November 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food & Drug Administration has cleared...
Titusville, New Jersey – November 6, 2025 – Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and...
